Non-Hodgkin lymphoma

Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for DZD4205 (Golidocitinib) for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma

Retrieved on: 
Friday, February 18, 2022

SHANGHAI, Feb. 18, 2022 /PRNewswire/ --Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to DZD4205 (Golidocitinib) for the treatment of patients with Refractory or Relapsed Peripheral T-Cell Lymphoma (r/r PTCL).

Key Points: 
  • SHANGHAI, Feb. 18, 2022 /PRNewswire/ --Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to DZD4205 (Golidocitinib) for the treatment of patients with Refractory or Relapsed Peripheral T-Cell Lymphoma (r/r PTCL).
  • "Relapsed or refractory peripheral T-cell lymphoma is an aggressive and rare type of non-Hodgkin lymphoma.
  • Couple years ago, our translational science team first identified JAK1 as a potential target for PTCL treatment.
  • "The FDA Fast Track Designation for DZD4205 is an important milestone and we look forward to working closely with the U.S. FDA to potentially bring this treatment to our patients."

DGAP-News: Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma

Retrieved on: 
Tuesday, February 15, 2022

Dr. Andrs Strassz, Chief Medical Officer of Heidelberg Pharma, commented: "It is an important step for Heidelberg Pharma to have the first patient dosed in our study.

Key Points: 
  • Dr. Andrs Strassz, Chief Medical Officer of Heidelberg Pharma, commented: "It is an important step for Heidelberg Pharma to have the first patient dosed in our study.
  • This Phase I/IIa study will test a new mode of action in oncology and is the first trial to evaluate an antibody drug conjugate carrying Amanitin as active component in patients.
  • For many patients with multiple myeloma, currently available therapies lead to relapses despite initial success, necessitating further treatment options.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0/ WKN A11QVV / Symbol HPHA.

Eduardo M. Sotomayor, MD, Appointed Chair of Lymphoma Research Foundation Mantle Cell Lymphoma Consortium

Retrieved on: 
Thursday, February 10, 2022

LRF has appointed Eduardo M. Sotomayor, MD, director of Tampa General Hospital's Cancer Institute, as chair of its Mantle Cell Lymphoma Consortium (MCLC) Executive Committee.

Key Points: 
  • LRF has appointed Eduardo M. Sotomayor, MD, director of Tampa General Hospital's Cancer Institute, as chair of its Mantle Cell Lymphoma Consortium (MCLC) Executive Committee.
  • The Mantle Cell Lymphoma Consortium Executive Committee helps to guide the MCLC by identifying gaps in research and patient care for this historically understudied patient population.
  • Since its inception in 2003, the Mantle Cell Lymphoma Workshop brings together leading international experts to discuss the latest research findings, foster collaboration within the mantle cell lymphoma (MCL) research community, create new directions for research, and ultimately improve diagnosis and treatment for this disease.
  • "Dr. Sotomayor is a world-renowned expert in mantle cell lymphoma and dedicated member of our prestigious Scientific Advisory Board," said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation.

CAR T-cell Therapy Drug Pipeline Market Research Report 2022: Insights About 300+ Companies and 300+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, February 7, 2022

This report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in CAR T-cell Therapy pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in CAR T-cell Therapy pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-cell Therapy R&D.
  • This segment of the report provides insights about the different CAR T-cell Therapy drugs segregated based on following parameters that define the scope of the report.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-cell Therapy drugs.

DGAP-News: iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development

Retrieved on: 
Thursday, February 3, 2022

Martinsried / Munich, Germany, 03 February, 2022 - iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, today announced the appointment of Dr. Murray Yule, M.D., Ph.D., as Chief Medical Officer (CMO), as of early January, 2022.

Key Points: 
  • Martinsried / Munich, Germany, 03 February, 2022 - iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, today announced the appointment of Dr. Murray Yule, M.D., Ph.D., as Chief Medical Officer (CMO), as of early January, 2022.
  • Murray is a board-certified medical oncologist with extensive experience in leading clinical development programs.
  • "I am delighted to join the outstanding team at iOmx at this important juncture and contribute to their successful transformation into a clinical stage organization.
  • Our lead program, IMT-07, is currently proceeding with Clinical Trial Application (CTA)-enabling studies and aims to enter clinical development in late 2022."

Environment and Human Health Inc. Calls for Roundup and Other Glyphosate Products to Become Registered-Use Pesticides

Retrieved on: 
Wednesday, February 2, 2022

Roundup is the trade name for the original Montsanto product that contained its own herbicide, glyphosate.

Key Points: 
  • Roundup is the trade name for the original Montsanto product that contained its own herbicide, glyphosate.
  • This new designation would remove these pesticide products from retail stores and would keep the public from using the product themselves.
  • "Roundup and glyphosate products are very commonly applied lawn and garden herbicides, and they threaten to contaminate both private and public drinking water supplies.
  • "Pregnant women should avoid using glyphosate, as this pesticide has been linked to premature births and other reproductive health effects.

Global LAG 3 Inhibitor Market Opportunity & Clinical Trials Insight Report 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022

The "Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • The key players in the market include MacroGenics, Zai Lab, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, among others.
  • Cancer immunotherapy is a novel approach which can reverse tumor immune escape by suppressing immune checkpoint pathways.
  • Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
    LAG 3 Inhibitors Trials By Phase, Company, Country, Indication

Incyte Provides Update on Parsaclisib and MCLA-145

Retrieved on: 
Tuesday, January 25, 2022

Incyte is withdrawing the New Drug Application (NDA) for parsaclisib for the treatment of patients with relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).

Key Points: 
  • Incyte is withdrawing the New Drug Application (NDA) for parsaclisib for the treatment of patients with relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).
  • The withdrawal of the NDA is a business decision and is not related to any changes in either the efficacy or safety of parsaclisib.
  • Additionally, as part of its ongoing portfolio prioritization and capital allocation review, Incyte has decided to opt-out of the continued development of MCLA-145.
  • In December 2018, Innovent and Incyte entered into a strategic collaboration for three clinical-stage product candidates, including parsaclisib.

CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Epidemiology Report 2022: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 25, 2022

The "CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • The CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) epidemiology report gives a thorough understanding of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • The report covers the detailed information of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) epidemiology scenario in seven major countries (US, EU5, and Japan).
  • The CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Epidemiology Report and Model provide an overview of the global trends of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA

Retrieved on: 
Thursday, January 20, 2022

A second Phase 1/2 trial is investigating BI-1206 in combination with anti-PD1 therapy Keytruda(pembrolizumab) in solid tumors.

Key Points: 
  • A second Phase 1/2 trial is investigating BI-1206 in combination with anti-PD1 therapy Keytruda(pembrolizumab) in solid tumors.
  • Dr. Wei-Wu He, CASI's Chairman, and CEO commented, "BioInvent continues to make progress with the development and regulatory framework for BI-1206.
  • The CTA approval in China in December 2021 and the recent FDA Orphan Drug Designation demonstrate the strong potential of this first-in-class antibody.
  • CASI and BioInvent are seamless partners and have the common goal to benefit patients with innovative pharmaceutical technologies."